This inventor holds 2 USPTO granted patents. Top assignee: Bayer Aktiengesellschaft. Active years: 1992-1993.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Wuppertal-Elberfeld, DE (1992)
- Wuppertal, DE (1993)
Company Filing History:
Years Active: 1992-1993
Title: Innovations by Jurgen Ebbers: A Look into His Contributions
Introduction
Jurgen Ebbers, an accomplished inventor based in Wuppertal-Elberfeld, Germany, has made significant strides in the field of biotechnology. With a total of two patents to his name, his work primarily focuses on genetic engineering and the development of novel medical ingredients. His innovations have the potential to influence therapeutic practices in the medical industry.
Latest Patents
Ebbers' most recent patents concern recombinant aprotinin variants, which are genetically engineered processes that feature an aprotinin with a deletion of the amino acid proline at position 2 or the addition of alanine-(-2)-glutamine-(-1). These engineered aprotinin variants serve as active ingredients in medicaments, showcasing Ebbers' commitment to advancing medical treatments through biotechnological innovation.
Career Highlights
Jurgen Ebbers is currently employed at Bayer Aktiengesellschaft, a leading global life sciences company. His work at Bayer has strengthened the company's portfolio in the biopharmaceutical sector, highlighting his role in significant research and development efforts. His patents demonstrate his ability to innovate and contribute effectively to the ongoing quest for improved medical solutions.
Collaborations
Throughout his career, Ebbers has collaborated with notable colleagues, including Dietrich Horlein and Michael Schedel. These partnerships have allowed for the exchange of ideas and expertise, enhancing the overall effectiveness of their research initiatives and driving successful outcomes in their projects.
Conclusion
Jurgen Ebbers represents a new generation of inventors who are pushing the boundaries of biotechnology. His work on recombinant aprotinin variants exemplifies the intersection of innovation and practical application in medicine. As he continues to contribute to Bayer and collaborates with peers, the impact of his inventions will likely resonate within the medical community for years to come.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile